FeaturedSparsentan is now approved to treat adult patients with primary immunoglobulin A nephropathy (IgAN)
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved new medicine containing active ingredient sparsentan to treat primary immunoglobulin A nephropathy (IgAN). IgA neuropathy, also known as…